Patents by Inventor Paul Joseph Dyson

Paul Joseph Dyson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Ionic polymers and use thereof in biomass processing
    Patent number: 11925925
    Abstract: The invention provides ionic polymers (IP) consisting of anions and a polymeric backbone containing cations. The invention also provides the ionic polymers incorporated in membranes or attached to solid supports and use of the ionic polymers in processing of biomass.
    Type: Grant
    Filed: September 19, 2018
    Date of Patent: March 12, 2024
    Assignee: Embion Technologies SA
    Inventors: Sviatlana Siankevich, Georgios Savoglidis, Paul Joseph Dyson, Zhaofu Fei
  • IONIC POLYMERS AND USE THEREOF IN BIOMASS PROCESSING
    Publication number: 20200246785
    Abstract: The invention provides ionic polymers (IP) consisting of anions and a polymeric backbone containing cations. The invention also provides the ionic polymers incorporated in membranes or attached to solid supports and use of the ionic polymers in processing of biomass.
    Type: Application
    Filed: September 19, 2018
    Publication date: August 6, 2020
    Inventors: Sviatlana Siankevich, Georgios Savoglidis, Paul Joseph Dyson, Zhaofu Fei
  • Direct carbon dioxide hydrogenation to formic acid in acidic media
    Patent number: 9399613
    Abstract: The present invention relates to a method of producing formic acid in a catalyzed chemical reaction from hydrogen gas and carbon dioxide gas, said reaction being conducted in an acidic medium comprising a polar solvent over a wide range of temperatures at total gas pressure of hydrogen and carbon dioxide up to 250 bar without the addition of base, carbonate, hydrogen carbonate or formate. The method of the present invention is advantageous since the reaction may be conducted in a polar solvent such as water or DMSO.
    Type: Grant
    Filed: February 10, 2014
    Date of Patent: July 26, 2016
    Assignee: Ecole Polytechnique Federale de Lausanne (EPFL)
    Inventors: Severine Moret, Paul Joseph Dyson, Gabor Laurenczy
  • DIRECT CARBON DIOXIDE HYDROGENATION TO FORMIC ACID IN ACIDIC MEDIA
    Publication number: 20160016875
    Abstract: The present invention relates to a method of producing formic acid in a catalysed chemical reaction from hydrogen gas and carbon dioxide gas, said reaction being conducted in an acidic medium comprising a polar solvent over a wide range of temperatures at total gas pressure of hydrogen and carbon dioxide up to 250 bar without the addition of base, carbonate, hydrogen carbonate or formate. The method of the present invention is advantageous since the reaction may be conducted in a polar solvent such as water or DMSO.
    Type: Application
    Filed: February 10, 2014
    Publication date: January 21, 2016
    Inventors: Severine Moret, Paul Joseph Dyson, Gabor Laurenczy
  • TRANSITION METAL COMPLEXES FOR INHIBITING RESISTANCE IN THE TREATMENT OF CANCER AND METASTASIS
    Publication number: 20150190362
    Abstract: The present invention relates to organometallic compounds useful in the treatment of metastasis. The organometallic compounds comprise a ligand that is convalently bound to a bioactive compound, which is an inhibitor of a resistance pathway or a derivative thereof. Preferably, the organometallic compounds are half-sandwich (“piano-stool”) compounds. The compounds of the present invention offer a high variability with respect to the bioactive compound and to the nature of the ligand bound to a central transition metal.
    Type: Application
    Filed: March 18, 2015
    Publication date: July 9, 2015
    Inventors: Paul Joseph Dyson, Wee Han Ang
  • Transition metal complexes for inhibiting resistance in the treatment of cancer and metastasis
    Patent number: 9018199
    Abstract: The present invention relates to organometallic compounds useful in the treatment of metastasis. The organometallic compounds comprise a ligand that is covalently bound to a bioactive compound, which is an inhibitor of a resistance pathway or a derivative thereof. Preferably, the organometallic compounds are half-sandwich (“piano-stool”) compounds. The compounds of the present invention offer a high variability with respect to the bioactive compound and to the nature of the ligand bound to a central transition metal.
    Type: Grant
    Filed: May 9, 2007
    Date of Patent: April 28, 2015
    Assignee: Ecole Polytechnique Federale de Lausanne (EPFL)
    Inventors: Paul Joseph Dyson, Wee Han Ang
  • Medicaments Based on Dinuclear Arene Ruthenium Complexes Comprising Bridging Thiolato, Selenolato or Alkoxo Ligands
    Publication number: 20130172408
    Abstract: The present invention provides new complexes and medicaments based on dinuclear ruthenium complexes comprising bridging thiolato or selenolato ligands. The complexes comprise a Ru2X3 or a Ru2X2 core, in which each one of said X is independently selected from said bridging ligands, with the proviso that at least one ligand comprises a substituted or unsubstituted phenyl moiety.
    Type: Application
    Filed: July 19, 2011
    Publication date: July 4, 2013
    Applicant: Universite de Neuchatel
    Inventors: Georg Suss-Fink, Bruno Therrien, Michael Gras, Paul Joseph Dyson, Olivier Zava, Anne-Flore Ibao
  • ORGANOMETEALLIC COMPOUNDS
    Publication number: 20100173885
    Abstract: The present invention relates to novel organometallic compounds for use as a medicine, in particular in photodynamic therapy against various diseases, such as cancer or inflammatory and/or immune disorders. The compounds comprise a central porphyrin or phtalocyanine backbone to which ligand linkers coordinated to at least one transition metal are attached. Eta-5 or eta-6 arenes further bind to the transition metal. According to a preferred embodiment, the compound is a tetranuclear Ruthenium (+II) complex.
    Type: Application
    Filed: January 25, 2008
    Publication date: July 8, 2010
    Inventors: Bruno Therrien, Govindasvamy Padavattan, Georg Sûss-Fink, Wee Han Ang, Paul Joseph Dyson, Lucienne Juillerat, Frédéric Schmitt
  • Transition Metal Complexes for Inhibiting Resistance in the Treatment of Cancer and Metastasis
    Publication number: 20090312301
    Abstract: The present invention relates to organometallic compounds useful in the treatment of metastasis. The organometallic compounds comprise a ligand that is covalently bound to a bioactive compound, which is an inhibitor of a resistance pathway or a derivative thereof. Preferably, the organometallic compounds are half-sandwich (“piano-stool”) compounds. The compounds of the present invention offer a high variability with respect to the bioactive compound and to the nature of the ligand bound to a central transition metal.
    Type: Application
    Filed: May 9, 2007
    Publication date: December 17, 2009
    Inventors: Paul Joseph Dyson, Wee Han Ang